# US 2022/0023197 A1 · Composition for treating or preventing skin pigmentation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0023197 A1
- Document ID: US20220023197A1
- Status: Published application
- Kind: A1
- Application number: 17/298,440
- Filed: 2019-11-29
- Published: 2022-01-27
- Earliest claimed: 2018-11-30
- Assignees: Shiseido Company, Ltd.
- Applicants: Shiseido Company, Ltd.
- Inventors: Sayaka KOIDE; Masaya TAKAGI; Shoko YAMADA; Ritsuro IDETA; Takashi SATOH
- Web page: https://patentgrep.com/patent/US20220023197A1

## CPC

- A61K 8/985: {Skin or skin outgrowth, e.g. hair, nails}
- A61P 17/00: Drugs for dermatological disorders
- A61K 8/982: {Reproductive organs; Embryos, Eggs}
- A61K 35/33: Fibroblasts
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 19/02: for chemically bleaching or whitening the skin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention provides a composition for treating or preventing skin pigmentation, which contains fibroblasts as an active ingredient, wherein the fibroblasts are those fibroblasts which are less damaged than fibroblasts localized in a site where the skin pigmentation occurs, and the composition is characterized by being intended to be applied to a site where the pigmentation occurs or a dermis tissue around the site.

## Claims

### Claim 1

A composition for treatment or prevention of skin pigmentation, containing fibroblasts as an active ingredient, wherein:
the fibroblasts are fibroblasts with less damage than fibroblasts localized at the site of skin pigmentation, and
the composition is applied to the site of pigmentation or its surrounding dermal tissue.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein the pigmentation is from one or more conditions selected from the group consisting of senile pigmentation spots, seborrheic keratosis, Chloasma, freckles and floriform pigmented spots.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein the fibroblasts are derived from biological tissue of a site with low light exposure or no light exposure.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the fibroblasts are derived from a tissue selected from the group consisting of the gluteal region, abdominal region, thorax, femoral region, upper arm, dorsal region, gingiva, oral mucosa, scalp, palms, foot soles and auricle rear.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the fibroblasts are autologous fibroblasts.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein the fibroblasts are fibroblasts differentiated from pluripotent stem cells or tissue stem cells.

### Claim 7 (depends on 1)

The composition according to claim 1, wherein the fibroblasts have lower expression of a cell senescence marker than fibroblasts localized at the site of skin pigmentation.

### Claim 8 (depends on 7)

The composition according to claim 7, wherein the cell senescence marker is one or more selected from the group consisting of senescent acidic β-galactosidase (SA-βgal), cell cycle check mechanism-associated factor and cell senescence-associated secretory phenotype (SASP) factor.

### Claim 9 (depends on 1)

The composition according to claim 1, which is to be applied by cell therapy.
